Neurodevelopment in children born to HIV-infected mothers by infection and treatment status

Pediatrics

Volumn 130, Issue 5, 2012, Pages

  Le Doaré, Kirsty ^a,b   Bland, Ruth ^c,d   Newell, Marie Louise ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antiretroviral therapy; Childhood development; HAART; HIV; Neurodevelopment

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ALCOHOL ABUSE; ANTIVIRAL THERAPY; CHILD BEHAVIOR; CHILD CARE; CHILD DEVELOPMENT; CHILDBIRTH; COGNITION; DEVELOPMENTAL DISORDER; DEVELOPMENTAL SCREENING; DRUG ABUSE; EARLY DIAGNOSIS; EARLY INTERVENTION; ENVIRONMENTAL EXPOSURE; EXECUTIVE FUNCTION; FETUS; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL DISEASE; MEMORY; MONOTHERAPY; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRIORITY JOURNAL; RACE DIFFERENCE; RESOURCE ALLOCATION; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; SPEECH DISORDER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

EID: 84868616911     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0405     Document Type: Review

References (88)

1. Report G. UNAIDS Report on the Global AIDS Epidemic 2010. WHO Geneva Library Cataloguing-in-Publication Data; 2010
2. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175-1182 (Pubitemid 30126606)
3. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS. 1997;(11 suppl B): S79-87
4. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: maternal immune status and obstetric factors. The European Collaborative Study. AIDS. 1996;10(14):1675-1681 (Pubitemid 26394986)
5. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105(8):836-848 (Pubitemid 28423498)
6. Habib NA, Daltveit AK, Bergsjø P, Shao J, Oneko O, Lie RT. Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study. BJOG. 2008;115(5):616-624 (Pubitemid 351357585)
7. Rollins NC, Coovadia HM, Bland RM, et al. Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South Africa. J Acquir Immune Defic Syndr. 2007;44(3):321-328 (Pubitemid 46328350)
8. Bulterys M, Chao A, Munyemana S, et al. Maternal human immunodeficiency virus 1 infection and intrauterine growth: a prospective cohort study in Butare, Rwanda. Pediatr Infect Dis J. 1994;13(2):94-100 (Pubitemid 24059158)
9. Taha TE, Dallabetta GA, Canner JK, et al. The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi. Int J Epidemiol. 1995;24(5):1022-1029 (Pubitemid 26434296)
10. Woythaler MA, McCormick MC, Smith VC. Late preterm infants have worse 24-month neurodevelopmental outcomes than term infants. Pediatrics. 2011;127(3). Available at: www.pediatrics.org/cgi/content/full/127/3/e622
11. Schendel DE, Stockbauer JW, Hoffman HJ, Herman AA, Berg CJ, Schramm WF. Relation between very low birth weight and developmental delay among preschool children without disabilities. Am J Epidemiol. 1997;146(9):740-749 (Pubitemid 27484008)
12. Karimi M, Fallah R, Dehghanpoor A, Mirzaei M. Developmental status of 5-year-old moderate low birth weight children. Brain Dev. 2011;33(8):651-655
13. Sharer LR. Pathology of HIV-1 infection of the central nervous system. A review. J Neuropathol Exp Neurol. 1992;51(1):3-11
14. Persidsky Y, Zheng J, Miller D, Gendelman HE. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol. 2000;68(3):413-422
15. Armstrong FD. Neurodevelopment and chronic illness: Mechanisms of disease and treatment. Ment Retard Dev Disabil Res Rev. 2006;12(3):168-173 (Pubitemid 44646325)
16. Kaul M, Lipton SA. Signaling pathways to neuronal damage and apoptosis in human immunodeficiency virus type 1-associated dementia: chemokine receptors, excitotoxicity, and beyond. J Neurovirol. 2004;10(suppl 1):97-101 (Pubitemid 38331918)
17. Epstein LG, Gelbard HA. HIV-1-induced neuronal injury in the developing brain. J Leukoc Biol. 1999;65(4):453-457 (Pubitemid 29160172)
18. Tardieu M. Update on the neurological consequences of HIV-1 infection (2006) [in French]. Rev Neurol (Paris). 2006;162(1):19-21 (Pubitemid 43217948)
19. Lobato MN, Caldwell MB, Ng P, Oxtoby MJ; Pediatric Spectrum of Disease Clinical Consortium. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. J Pediatr. 1995;126(5 pt 1):710-715
20. Englund JA, Baker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Pediatr Infect Dis J. 1996;15(11):1025-1036 (Pubitemid 26403799)
21. Neurologic signs in young children with human immunodeficiency virus infection. The European Collaborative Study. Pediatr Infect Dis J. 1990;9(6):402-406
22. Ojukwu IC, Epstein LG. Neurologic manifestations of infection with HIV. Pediatr Infect Dis J. 1998;17(4):343-344 (Pubitemid 28208211)
23. Newton HB. Common neurologic complications of HIV-1 infection and AIDS. Am Fam Physician. 1995;51(2):387-398
24. Johann-Liang R, Lin K, Cervia J, Stavola J, Noel G. Neuroimaging findings in children perinatally infected with the human immunodeficiency virus. Pediatr Infect Dis J. 1998;17(8):753-754 (Pubitemid 28388170)
25. Lacroix C, Vazeux R, Brousse N, Blanche S, Tardieu M. A neuropathological study of 10 HIV-infected children [in French]. Rev Neurol (Paris). 1993;149(1):37-45
26. Letendre S, Marquie-Beck J, Capparelli E, et al CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70
27. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR III; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23(14):1893-1901
28. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr. 2005;146(3):402-407 (Pubitemid 40347260)
29. McCoig C, Castrejón MM, Castaño E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr. 2002;141(1):36-44 (Pubitemid 34774949)
30. Nachman SA, Chernoff M, Gona P, et al; PACTG 219C Team. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171
31. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunode ficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-1180
32. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr. 1997;131(6):857-862 (Pubitemid 28027610)
33. European Collaborative Study. Mother-tochild transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458-465
34. Townsend C, Schulte J, Thorne C, et al Pediatric Spectrum of HIV Disease Consortium, the European Collaborative Study and the National Study of HIV in Pregnancy and Childhood. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG. 2010;117(11):1399-1410
35. Townsend CL, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. Antivir Ther. 2010;15(5):775-783
36. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282-2294
37. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506-514
38. van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42
39. Olagbuji BN, Ezeanochie MC, Ande AB, Oboro VO. Obstetric and perinatal outcome in HIV positive women receiving HAART in urban Nigeria. Arch Gynecol Obstet. 2010;281(6):991-994
40. Engle PL, Black MM, Behrman JR, et al International Child Development Steering Group. Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. Lancet. 2007;369(9557):229- 242 (Pubitemid 46107686)
41. Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B; International Child Development Steering Group. Developmental potential in the first 5 years for children in developing countries. Lancet. 2007;369(9555):60-70 (Pubitemid 46027229)
42. World Health Organization. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. WHO Library Cataloguing-in-Publication Data; Geneva, Switzerland; 2010
43. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-341
44. Pollack H, Kuchuk A, Cowan L, et al. Neurodevelopment, growth, and viral load in HIV-infected infants. Brain Behav Immun. 1996;10(3):298-312 (Pubitemid 27007856)
45. Nozyce M, Hittelman J, Muenz L, Durako SJ, Fischer ML, Willoughby A. Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. Pediatrics. 1994;94(6 pt 1):883-891 (Pubitemid 24359193)
46. Chase C, Vibbert M, Pelton SI, Coulter DL, Cabral H. Early neurodevelopmental growth in children with vertically transmitted human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995;149(8):850-855
47. Chase C, Ware J, Hittelman J, et al Women and Infants Transmission Study Group. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Pediatrics. 2000;106(2). Available at: www.pediatrics.org/cgi/content/full/106/2/E25
48. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281(2):151-157 (Pubitemid 29045347)
49. Raskino C, Pearson DA, Baker CJ, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics. 1999;104(3). Available at: www.pediatrics.org/cgi/content/full/104/3/e32
50. Smith R, Malee K, Charurat M, et al The Women and Infant Transmission Study Group. Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. Pediatr Infect Dis J. 2000;19(9):862-871
51. Blanchette N, Smith ML, King S, Fernandes-Penney A, Read S. Cognitive development in school-age children with vertically transmitted HIV infection. Dev Neuropsychol. 2002;21(3):223-241 (Pubitemid 34977150)
52. Llorente A, Brouwers P, Charurat M, et al Women and Infant Transmission Study Group. Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. Dev Med Child Neurol. 2003;45(2):76-84 (Pubitemid 36798203)
53. Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125(2). Available at: www.pediatrics.org/ cgi/content/full/125/2/e250 doi:10.1542/peds.2009-1112
54. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118(4). Available at: www.pediatrics.org/cgi/content/full/118/4/e1139
55. Lindsey JC, Malee KM, Brouwers P, Hughes MD; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119(3). Available at: www.pediatrics.org/cgi/content/full/119/3/e681
56. Levenson RL Jr, Mellins CA, Zawadzki R, Kairam R, Stein Z. Cognitive assessment of human immunode ficiency virus-exposed children. Am J Dis Child. 1992;146(12):1479-1483
57. Fishkin PE, Armstrong FD, Routh DK, et al. Brief report: relationship between HIV infection and WPPSI-R performance in preschool-age children. J Pediatr Psychol. 2000;25(5):347-351 (Pubitemid 30471169)
58. Brackis-Cott E, Kang E, Dolezal C, Abrams EJ, Mellins CA. The impact of perinatal HIV infection on older school-aged children's and adolescents' receptive language and word recognition skills. AIDS Patient Care STDS. 2009;23(6):415-421
59. Jeremy RJ, Kim S, Nozyce M, et al; Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics. 2005;115(2):380-387 (Pubitemid 43193822)
60. Smith R, Malee K, Leighty R, et al Women and Infants Transmission Study Group. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics. 2006;117(3):851-862 (Pubitemid 46063229)
61. Blanchette N, Smith ML, Fernandes-Penney A, King S, Read S. Cognitive and motor development in children with vertically transmitted HIV infection. Brain Cogn. 2001;46(1-2):50-53 (Pubitemid 32466573)
62. Bisiacchi PS, Suppiej A, Laverda A. Neuropsychological evaluation of neurologically asymptomatic HIV-infected children. Brain Cogn. 2000;43(1-3):49-52 (Pubitemid 30398643)
63. Caplo A, Sa CA, Rubini N, Silva E, Azevedo M, Kalil R. The importance of early neurological delay detection of vertically HIV-infected children. In: AIDS 2008-XVII International AIDS conference; August 3-8, 2008; Mexico City, Mexico. Abstract Number WEPE0227
64. Foster CJ, Biggs RL, Melvin D, Walters MD, Tudor-Williams G, Lyall EG. Neurodevelopmental outcomes in children with HIV infection under 3 years of age. Dev Med Child Neurol. 2006;48(8):677-682 (Pubitemid 44044472)
65. Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. Eur J Paediatr Neurol. 2008;12(4):290-297 (Pubitemid 351680713)
66. Thomaidis L, Bertou G, Critselis E, Spoulou V, Kafetzis DA, Theodoridou M. Cognitive and psychosocial development of HIV pediatric patients receiving highly active antiretroviral therapy: a case-control study. BMC Pediatr. 2010;10:99
67. Ferguson G, Jelsma J. The prevalence of motor delay among HIV infected children living in Cape Town, South Africa. Int J Rehabil Res. 2009;32(2):108-114
68. Kandawasvika G, Gumbo F, Kurewa E, Mapingure P. Risk factors for neurodevelopment impairment among infants born to HIV infected mothers in Harare, Zimbabwe. IAS 2011; July 17-20, 2011; Rome, Italy. Abstract No. WEPE0068
69. Laughton B, Grove D, Kidd M, et al. Early antiretroviral therapy is associated with improved neurodevelopmental outcome in HIV infected infants: Evidence from the CHER (Children with HIV Early Antiretroviral therapy) trial. Vancouver, Canada: IAS; 2009
70. Potterton J, Stewart A, Cooper P, Goldberg L, Gajdosik C, Baillieu N. Neurodevelopmental delay in children infected with HIV in Soweto, South Africa. Vulnerable Child Youth Stud. 2009;4(1):48-57
71. Smith L, Adams C, Eley B. Neurological and neurocognitive function of HIV-infected children commenced on antiretroviral therapy. South African Journal of Child Health. 2008;2(3):108-113
72. Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics. 2008;122(1). Available at: www.pediatrics.org/cgi/ content/full/122/1/e123
73. Gay CL, Armstrong FD, Cohen D, et al. The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months. Pediatrics. 1995;96(6):1078-1082
74. Leartvanangkui C, Voramongkoi N, Jungpanich P, Chunhakuntarose P, Pattarakulvanich S. Growth and development of children born to HIV-positive pregnant women in 4 provinces in Thailand, 207-2008. In: 5th IAS Conference on HIV Pathogenesis and Treatment; July 2009; Vancouver, Canada. Abstract number CDC025
75. Bayley N. Bayley Scales of Infant Development. San Antonio, TX: Psychological Corporation; 1993
76. Blanche S, Tardieu M, Duliege A, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child. 1990;144(11):1210-1215 (Pubitemid 20360621)
77. Wechsler D. Wechsler Intelligence Scale for Children-Revised. New York, NY: Psychological Corporation; 1974
78. McCarthy D. McCarthy Scales of Children's Abilities. San Antonio, TX: Psychological Corporation; 1972
79. Boivin MJ, Green SD, Davies AG, Giordani B, Mokili JK, Cutting WA. A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychol. 1995;14(1):13-21
80. Msellati P, Lepage P, Hitimana DG, Van Goethem C, Van de Perre P, Dabis F. Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda. Pediatrics. 1993;92(6):843-848 (Pubitemid 23351141)
81. Frankenburg WK, Dodds JB. The Denver Developmental Screening Test. Denver, CO: LADOCA; 1969
82. Kube DA, Wilson WM, Petersen MC, Palmer FB. CAT/CLAMS: its use in detecting early childhood cognitive impairment. Pediatr Neurol. 2000;23(3):208-215
83. Griffiths R. The Abilities of Babies: A Study in Mental Measurement. New York, NY: McGraw-Hill; 1954:229
84. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20(9):1289-1294
85. Janssen N, Ndirangu J, Newell ML, Bland RM. Successful paediatric HIV treatment in rural primary care in Africa. Arch Dis Child. 2010;95(6):414-421
86. UNAIDS. 2008 report on the global AIDS epidemic. Updated 2008. Available at: http://www.unaids.org/en/dataanalysis/knowyourepidemic/ epidemiologypublications/2008reportontheglobalaidsepidemic/. Accessed March 17, 2011
87. Ndirangu J, Newell ML, Tanser F, Herbst AJ, Bland R. Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? AIDS. 2010;24(4):593-602
88. Patel K, Hernán MA, Williams PL, et al; Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46(4):507-515 (Pubitemid 351263487)